Review

Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases

E. Miserocchi,⁎ I. Pontikaki, G. Modorati, M. Gattinara, P.L. Meroni, V. Gerloni

A R T I C L E  A B S T R A C T

Rituximab is a monoclonal antibody directed against the CD20 antigen expressed on B cells and widely used in the treatment of non-Hodgkin’s lymphoma and rheumatoid arthritis. There is a growing amount of literature which suggests that rituximab may be useful for inflammatory ocular diseases and intraocular lymphoma. Few cases have been reported on treatment of refractory scleritis, peripheral ulcerative keratitis, uveitis and ocular surface inflammatory disorders. Rituximab may be effective in the treatment of ocular inflammatory diseases in particular the most aggressive, recalcitrant and sight-threatening forms of inflammation such as uveitis associated to juvenile idiopathic arthritis.

We review the literature covering the use of Rituximab in these conditions and report our results on the efficacy of Rituximab in the treatment of 8 children with very severe and long-standing uveitis who failed to respond to one or more TNF blockers. Our patients showed improvement in activity of uveitis, reduction of concomitant corticosteroids and immunosuppressants after a mean follow-up time of 14.87 months on rituximab. No serious adverse events were encountered in our treated patients.

Although further studies are needed for assessing the efficacy of rituximab and the exact dosing regimen, rituximab may be considered as a treatment alternative in patients with the most aggressive forms of inflammatory ocular diseases who fail to respond to conventional and anti-TNF immunosuppressive agents.

© 2011 Elsevier B.V. All rights reserved.

1. Rituximab

Anti CD20 Rituximab is a chimeric (murine and human) monoclonal antibody directed against the CD20 molecule, a tetraspan membrane protein found only on the surface of mature B cells [1–6]. The CD20 molecule displays a dynamic appearance first evolving in the immature
B cell stage and later disappearing when B cells differentiate into plasma cells. By targeting CD20 the killing of B-cell precursor stem cells is avoided. Long-lived plasma cells residing in the bone marrow are also spared as most of them do not any longer carry the CD20 antigen. This means that immunoglobulin formation against isoantigens and antibodies against previously fought infectious agents are continuously formed. The mechanism at which Rituximab causes B-cell death is not fully understood. It is, however, likely to be a combination of antibody-dependent cell-mediated cytotoxicity, complement-mediated lysis, growth inhibition and apoptosis. In vivo experiments using a mouse model of immunotherapy suggest that the most important mechanism of action is via antibody-dependent cell-mediated cytotoxicity [1-6]. The mechanisms do, however, work in a complex manner. For example, lymphoma cells at different maturation stages respond differently to Rituximab induced apoptosis and inhibition of proliferation.

Rituximab was first approved by the FDA in 1997 for treatment of patients with relapsed or refractory lymphoma. Since that time, its therapeutic range has gradually expanded to also include non-malignant B-cell dependent diseases. Of these, rheumatoid arthritis (RA) is the autoimmune disease in which Rituximab has been most extensively studied [4-8].

2. Drug safety and adverse events

The tolerability and safety of Rituximab has been well described in the clinical trials of patients with RA and review articles on non-Hodgkin’s lymphoma [4-7-10]. The most frequent adverse events are infusion reactions (30-35% with the first infusion). Patients may experience immediate infusion reactions of mild and transient character [4,7-11]. Nevertheless, severe infusion reactions are uncommon and their frequency is reduced by the use of concomitant intravenous steroids. Serum sickness reactions occur more frequently in patients with autoimmune diseases. As Rituximab is a chimeric human/mouse antibody, human antichimeric antibodies (HACAs) may occur and have been reported in about 9.2% of patients with RA. These HACAs may be responsible for infusion reactions [9,10].

The main concern with the use of Rituximab in the treatment of autoimmune diseases, especially when used with concomitant immunosuppressive therapy, is the high incidence of systemic infections, which can sometimes lead to fatal sepsisemia [9-11]. Variable degrees of rituximab-associated infectious risk have been reported. Some patients with refractory autoimmune diseases, who were treated with combined rituximab and immunosuppressants, developed infectious complications. Conversely, no infectious complications have been reported for patients in whom Rituximab was initiated alone, without systemic corticosteroids or other immunosuppressants [10]. To date, no studies comparing the infectious risk of conventional immunosuppressants versus Rituximab are available.

3. Rituximab in systemic autoimmune diseases

Several clinical studies have demonstrated the substantial impact of rituximab for treatment of various systemic autoimmune diseases [1-3,8-10-17]. Evidence of therapeutic effect is also mounting for numerous autoimmune conditions such as rheumatoid arthritis, systemic lupus erythematous (SLE), Wegener’s granulomatosis and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, idiopathic thrombocytopenic purpura, multiple sclerosis and Sjogren’s syndrome [4,7,12-15]. However, the treatment protocols applied in these studies differ from each other in that infusions were given once weekly for 2 to 4 weeks, and the dosages were either fixed at 500 mg or 2000 mg or were 375 mg/m² in other studies. A sustained B-cell depletion of naïve and autoimmune cells was achieved, with peripheral blood CD20 cells being low or undetectable for up to 6 months, returning to pretreatment levels within 12 months. Earlier repopulation of B cells was observed after rituximab monotherapy rather than after combination therapy with immunosuppressive agents, such as methotrexate [2].

4. Rituximab in inflammatory eye diseases

Rituximab has been successfully used for the treatment of refractory keratoconjunctivitis, scleritis [18-23], peripheral ulcerative keratitis [24,25], uveitis [26-29] and ocular surface inflammatory diseases such as cicatricial pemphigoid [30,31] also when associated with systemic diseases. Experience in inflammatory ocular diseases is still scarce with few case reports on its efficacy.

5. Scleritis and orbital inflammation

Necrotizing scleritis and peripheral ulcerative keratitis are destructive forms of ocular inflammation of Wegener’s granulomatosis usually associated with active systemic vasculitis and can result in profound visual loss. Successful effectiveness with Rituximab has been reported on three patients with scleritis and periocular ulcerative keratitis associated with Wegener’s granulomatosis [18,20-23]. Another case of periocular ulcerative keratitis associated with Wegener’s granulomatosis completely resolved with two Rituximab infusions, given according to the protocol of 1000 mg/infusion at two weeks apart [24]. Some authors showed limited evidence that scleritis and orbital inflammation may respond to Rituximab, probably due to the presence of fibrotic nature of granulomas in Wegener’s, especially when occurring retro-orbital [22]. Taylor and colleagues reported clinical improvement in 10 patients with refractory granulomatous ocular Wegener’s mainly scleritis and orbital granulomas [21]. In the study by Taylor, patients were treated with 2 doses of 1 mg each, 2 weeks apart, and B cell depletion was associated with a trend toward decreased ANCA levels and clinical improvement in both vasculitic and granulomatous manifestations of the disease [21]. Ahmadi-Simab and colleagues reported a case of refractory anterior scleritis associated with Sjögren’s syndrome that completely resolved after four infusions of Rituximab given according to the oncologic protocol at the dose of 375 mg/m² at four-week intervals [19]. It is possible that the different dosing regimens used for refractory orbital inflammation associated with Wegener granulomatosis may be responsible for the reported different responses.

6. Sjogren’s syndrome

Keratoconjunctivitis sicca (KCS) is the most common ocular manifestation of Sjogren’s syndrome; sicca syndrome, secondary to lacrimal gland inflammation and reduction of lacrimal tear secretion can induce severe corneal complications and may eventually lead to bilateral blindness.

Preliminary experiences of Rituximab therapy in Sjogren’s syndrome patients suggest that patients with more residual exocrine gland function might benefit from treatment. Sicca syndrome responded much better in the patient’s perspective than in clinical objective evaluation, with about half of the patients reporting an improvement in oral and ocular dryness, while objective tests (Schirmer test) remained unchanged or worsened in all the patients [16,17]. Improvement in submandibular flow rate, dry mouth score, IgM rheumatoid factors (RF), fatigue, and health-related quality of life tests, was also observed in Sjogren’s patients after treatment with Rituximab [17].

7. Ocular cicatricial pemphigoid

Ocular cicatricial pemphigoid (OCP) is one of the subsets within the spectrum of mucous membrane pemphigoid, a family of autoimmune blistering diseases with autoantibodies targeting various glycoproteins in skin and/or mucous membranes [30]. The disease is relentlessly progressive, usually slow, and often resulting in profound
visual disability. Foster and colleagues reported effective results on twelve patients with OCP treated with a combination of Rituximab and intravenous immunoglobulin therapy [31].

8. Intraocular lymphoma

Primary intraocular lymphoma, is a hematopoietic tumor that arises within the retina, vitreous, subretinal pigment epithelial space or optic nerve head. Intraocular lymphoma may manifest with different forms of uveitis called “masquerade syndrome”. The malignancy is considered a subset of primary central nervous system lymphoma, which is a variant of extra-nodal non Hodgkin lymphoma. Malignant lymphocytes present in intraocular lymphoma express certain B cell markers including CD 20 [32]. Therefore, intraocular use of rituximab has been explored in animal models. No ocular toxicity was found in rabbits and in humans treated with 1 mg of Rituximab injected in the vitreous cavity. Further studies are necessary to confirm the lack of toxicity at this dose and whether this local therapy is effective in human intraocular lymphoma [32,33].

9. Uveitis

Rituximab may be helpful in selected patients with chronic uveitis refractory to corticosteroid and conventional immunosuppressants. Tappeiner and colleagues reported improvement of endogenous uveitis and associated cystoid macular edema in an adult patient treated with Rituximab; the treatment also displayed a steroid-sparing effect. However, the B-cell depletion in the peripheral blood and the positive effect on uveitis were transient, since there was a recurrence of inflammation after 6 and 9 months from Rituximab treatment [26].

Davatchi and Sadreddini showed favorable results on the efficacy of Rituximab in intractable ocular lesions of patients with Behcet’s disease, in spite of the fact that it is mainly a T-cell driven disease [27,28].

10. Children with juvenile idiopathic arthritis associated uveitis: personal experience

Juvenile idiopathic arthritis (JIA) is the most common systemic disorder associated with uveitis in childhood, accounting for approximately 75% of all pediatric anterior uveitis cases. Long-term ocular complications of uveitis such as cataract, band keratopathy, posterior synechia, glaucoma and maculopathy can lead to severe visual impairment in about 38% of patients [34]. Visual outcome in long-term follow-up of patients suffering from JIA-associated uveitis has been described as poor, with one third of patients developing substantial visual impairment and 10% becoming blind [34]. Aggressive immunomodulatory therapy is often introduced to improve the visual prognosis and to reduce corticosteroid associated adverse events. With the advent of biologic agents, tumor necrosis factor α (TNFα) antagonists have been successfully used and have changed and markedly improved the treatment options for JIA [35–37]. However, a subset of patients fails to respond to TNFα blockers or is unable to tolerate these therapies and may benefit from switching to another drug.

B cells are clearly involved in the pathogenesis of oligoarticular JIA and associated uveitis, as suggested not only by the very strong association with ANA production in this JIA subset, but also by recent studies on peripheral blood mononuclear cells gene expression profile showing that B cell receptors signaling pathways is strongly upregulated in patients with persistent oligoarthritis [38]. Therefore B cells may be a rational target of biological treatment in JIA associated uveitis. Based on this and on the favorable response in inducing long-term remissions in different ocular and rheumatic inflammatory diseases, we decided to treat with Rituximab eight patients with recalcitrant and longstanding chronic JIA associated uveitis. We previously reported our preliminary experience with Rituximab in children with uveitis associated with JIA [39].

All patients attended the Pediatric Rheumatologic Unit at the “Istituto Ortopedico G. Pini”, Milan and were always under the care of the same uveitis specialist (EM). Patients included in the study were those who had an inadequate response in controlling intra-ocular inflammation to one or more TNF blockers (Etanercept, Infliximab or Adalimumab). Rituximab was given at the dose of 1000 mg per infusion on days 1 and 15 and a recall 3rd infusion was scheduled at 12th month and 21 months according to the rheumatologic protocol applied in the treatment of rheumatoid arthritis. Before Rituximab infusion, to prevent the onset or reduce the frequency and severity of infusion reactions, all patients received 100 mg of methylprednisolone intravenously, oral paracetamol and antihistamines. Screening before initiation of Rituximab treatment included serum biochemical and hematologic profiles with complete hemogram, liver and renal function tests, peripheral blood B lymphocytes count, chest X-ray and electrocardiography. All patients have been already pre-screened for the presence of active or latent tuberculosis since they have been previously treated with TNF-blockers.

Ophthalmic and rheumatologic assessments were performed every one or two months according to disease activity and response to treatment. All patients were clinically monitored by the same pediatric rheumatologist (IP) with complete physical examination and routine laboratory test, repeated at each office visit. Data collected included: age, gender, age at onset of uveitis and arthritis, characteristics of the uveitis, ocular complications, JIA category according to ILAR classification [40], presence of ANA, RF and HLA-B27 antigens, previous systemic immunosuppressant therapies, previous local (ocular) corticosteroid therapy, number and dosage of Rituximab infusions, and follow-up on Rituximab treatment.

The primary outcome measures evaluated were: clinical response to treatment including decrease in disease activity (intra-ocular inflammation), improvement in visual acuity, reduction of concomitant local and systemic corticosteroid and/or immunosuppressants, occurrence of adverse events. Disease activity was graded in accordance with the standardization uveitis nomenclature (SUN) criteria [41]. Anterior chamber cells, as a validated indicator for inflammatory activity and Snellen visual acuity were graded before treatment and at every ophthalmologic assessment.

Eight Caucasian patients (2 males and 6 females; 14 affected eyes) with a mean age of 20.26±6.6 (SD) years (range: 13–34) affected by JIA (oligo-extended in 5 patients, oligo-persistent in 2) and associated uveitis were treated with Rituximab. Treatment indication was active uveitis and failure to conventional immunosuppressants and anti-TNF agents (Etanercept, Infliximab, Adalimumab) due to inadequate response. All patients were ANA positive and negative for RF and HLA-B27 antigens. The mean age at onset of arthritis was 2.8±2.4 (SD) years (range 1–8), while the mean age at onset of uveitis was 4.1±3.9 (SD) years (range 1–12); the mean ocular disease duration was 16.12 years (range 11–26) and the mean duration of arthritis was 17.35 years (range 11–26). In six out of eight patients the ocular involvement was bilateral (total number of treated eyes: 14). Ocular complications present at the beginning of Rituximab treatment were: posterior synechia (13 out of 14 affected eyes), cataract (8/14 eyes), band keratopathy (11/14 eyes), glaucoma (5/14 eyes). Table 1 shows the details of previous and concomitant treatments for each patient.

Before starting the Rituximab treatment, all patients have been unsuccessfully treated with different consecutive TNFα blockers; patients #4 and #6 were switched on two agents, while the remaining patients underwent a switch of three different anti-TNF. The reason for switching among anti-TNF was either inefficacy on the uveitis or occurrence of adverse events. Patients #5 and #8 were also treated with a short-term course of chlorambucil before and after being treated with TNF blockers. Although long-term remission with
Chlorambucil agents have been previously reported in our experience with JIA associated uveitis patients [42], two of our patients failed to respond to this immunosuppressive agent. Patients #5 and #8, before or after switching of three anti-TNF drugs, have also tried a one-year course of Chlorambucil treatment with long-term remission but flare up of the uveitis after cessation of the alkylating agent.

The mean systemic prednisolone dose needed before Rituximab treatment was 18.75 mg/day (range 7.5–25 mg). At the end of follow-up, only four out of six patients were still on daily systemic low-doses of prednisolone (2.5–12.5 mg). The six patients treated with systemic prednisolone were able to greatly reduce the number of daily topical corticosteroid drops, from a mean of 3.25 (range 6–2) to a mean of 0.8 (range 2–0) times a day, and the remaining two patients were able to discontinue topical therapy.

The mean follow-up time on Rituximab was 14.87 ± 7.12 (SD) months (range: 7–25). Four out of eight patients (#1, #2, #4 and #7) underwent the 3rd Rituximab recall infusion after 8–12 months from the first one, and one patient #3 underwent the 4th recall infusion after 21 months from the first one, while the remaining received only the first full course of therapy of two infusions (Table 2).

Seven out of eight patients achieved the complete control of the uveitis and were on persistent clinical remission at the last visit. Patient #1 displayed a recurrence of anterior uveitis that resolved with topical corticosteroids, at 10th month after the first infusion of Rituximab. Patient # 3 had two recurrences respectively at 8th and 21 months, and underwent to an early recall 3rd and 4th infusion.

The decrease in uveitis activity was evident around the 4th–5th month after the first infusion. Snellen visual acuity measurements of each patient at the beginning of Rituximab and at last visit are shown in Table 2. None of the patients had a visual worsening during the follow-up, while one patient (#2) had a visual acuity improvement of the left eye being able to undergo cataract surgery while on clinical remission on Rituximab treatment. No serious adverse events were encountered in our treated patients.

The uveitis was on clinical remission in seven out of eight patients at the last visit and improvement of intra-ocular inflammation was noticeable around the 4th month after the first infusion of Rituximab.

A corticosteroid sparing effect of Rituximab was noticeable in all our patients; four out of six patients taking systemic prednisolone were still on tapering daily low doses at the end of follow-up, but the dosage was significantly reduced compared to that required at the beginning of Rituximab (mean reduction −11.7 mg/day; range −7.5 to −15), and two patients discontinued systemic steroid therapy at the end of follow-up. There was also a discontinuation of concomitant systemic immunosuppressants in five out of eight patients; only three patients were taking methotrexate and/or cyclosporine in association with Rituximab treatment at last visit.

Although experience in inflammatory eye disease is scarce, and definite conclusions cannot be drawn by our series because of its retrospective nature and the number of patients we believe that Rituximab may be a promising treatment option for refractory uveitis associated with JIA.

**Take-home messages**

- Rituximab, a humanized monoclonal antibody targeted to CD20, has been used extensively for treating systemic lymphoma, rheumatoid arthritis and other autoimmune diseases.
- Rituximab may be effective in the treatment of ocular inflammatory diseases in particular the most aggressive, recalcitrant and sight-threatening forms of inflammation such as uveitis in children associated with JIA, as well as diseases not responsive to anti-TNF alpha blocking agents.
- Inflammatory ocular diseases treated with Rituximab include: scleritis, peripheral ulcerative keratitis, keratoconjunctivitis sicca, uveitis, ocular cicatricial pemphigoid and intraocular lymphoma.
- Rituximab does not cure the disease and recurrences of inflammation are possible; retreatment may be required after variable periods of clinical remission.
- Studies in larger numbers of patients are needed to better evaluate the efficacy, dosing regimen, and safety.

**Table 1**

<table>
<thead>
<tr>
<th>Pr no.</th>
<th>Immunosuppressants employed before rituximab</th>
<th>Anti-TNF drugs employed before rituximab (switch)</th>
<th>Immunosuppressants at last visit</th>
<th>Systemic steroid before rituximab and at last visit (prednisolone mg/day)</th>
<th>Topical steroids before rituximab and at last visit (daily frequency)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>MTX, CSA</td>
<td>Etan, Inf, Adal</td>
<td>None</td>
<td>7.5–None</td>
<td>3–1</td>
</tr>
<tr>
<td>2</td>
<td>MTX, CSA</td>
<td>Etan, Inf, Adal</td>
<td>None</td>
<td>25–12.5</td>
<td>4–1</td>
</tr>
<tr>
<td>3</td>
<td>MTX, CSA</td>
<td>Etan, Inf, Adal</td>
<td>None</td>
<td>None–None</td>
<td>4–2</td>
</tr>
<tr>
<td>4</td>
<td>MTX, CSA</td>
<td>Inf, Adal</td>
<td>CSA</td>
<td>25–12.5</td>
<td>3–1</td>
</tr>
<tr>
<td>5</td>
<td>MTX, CSA, CHLOR</td>
<td>Etan, Inf, Adal</td>
<td>MTX</td>
<td>20–12.5</td>
<td>6–0</td>
</tr>
<tr>
<td>6</td>
<td>MTX, CSA</td>
<td>Etan, Inf</td>
<td>None</td>
<td>15–None</td>
<td>2–0</td>
</tr>
<tr>
<td>7</td>
<td>MTX</td>
<td>Etan, Inf, Adal</td>
<td>MTX, CSA</td>
<td>None–None</td>
<td>2–1</td>
</tr>
<tr>
<td>8</td>
<td>MTX, CSA, CHLOR</td>
<td>Etan, Inf, Adal</td>
<td>None</td>
<td>20–2.5</td>
<td>2–1</td>
</tr>
</tbody>
</table>

Legend: MTX: methotrexate; CSA: cyclosporine; CHLOR: chlorambucil; Etan: etanercept; Inf: infliximab; and Adal: adalimumab.

**Table 2**

<table>
<thead>
<tr>
<th>Pr no. of uveitis at last visit</th>
<th>Recurrence of uveitis (months from first infusion)</th>
<th>Follow-up time on rituximab (months)</th>
<th>Visual acuity before rituximab</th>
<th>Visual acuity at last visit</th>
<th>No. of rituximab infusions (1000 mg: dose at each infusion)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 No</td>
<td>10</td>
<td>25</td>
<td>20/40; NLP</td>
<td>20/40; NLP</td>
<td>3</td>
</tr>
<tr>
<td>2 No</td>
<td>No</td>
<td>23</td>
<td>20/40; 20/200</td>
<td>20/40; 20/40</td>
<td>3</td>
</tr>
<tr>
<td>3 Yes</td>
<td>8, 21</td>
<td>21</td>
<td>20/20; 20/20</td>
<td>20/20; 20/20</td>
<td>4</td>
</tr>
<tr>
<td>4 No</td>
<td>No</td>
<td>14</td>
<td>20/20; 20/25</td>
<td>20/20; 20/25</td>
<td>3</td>
</tr>
<tr>
<td>5 No</td>
<td>No</td>
<td>11</td>
<td>20/40; 20/60</td>
<td>20/40; 20/60</td>
<td>2</td>
</tr>
<tr>
<td>6 No</td>
<td>No</td>
<td>10</td>
<td>20/20; 20/20</td>
<td>20/20; 20/20</td>
<td>2</td>
</tr>
<tr>
<td>7 No</td>
<td>No</td>
<td>8</td>
<td>20/20; 20/20</td>
<td>20/20; 20/20</td>
<td>3</td>
</tr>
<tr>
<td>8 No</td>
<td>No</td>
<td>7</td>
<td>NLP; 20/60</td>
<td>NLP; 20/60</td>
<td>2</td>
</tr>
</tbody>
</table>

Legend. NLP: no light perception.

**References**

Antiphospholipid antibodies affect human endometrial angiogenesis.

A large variety of autoantibodies are described in patients affected with polymyxositis (PM) or dermatomyositis (DM), generally associated with clinically distinct disease subsets, or with myositis overlap syndrome. More recently anti-155/140 and anti-CADM-140 autoantibodies have been described and clinical and prognostic correlations of these antibodies are still under investigation.

In a large multicenter cross-sectional Japanese study (Arch Dermatol 2011; 147:391-8) anti-Mi-2, anti-155/140, and anti-CADM-140 autoantibodies were investigated in 376 Japanese patients affected in DM in order to clarify the correlations between these three DM specific antibodies and clinical features and prognosis. Patients with PM, systemic sclerosis, and systemic lupus erythematosus were also considered in the analysis.

These antibodies were found only in patients affected in DM, and not in patients affected with other autoimmune disease. Anti-Mi-2 antibodies, found positive in 2% of DM cases were associated without pulmonary involvement; anti-155/140 antibodies found positive in 7% of cases were associated with malignancy; finally, anti-CADM-140 positive patients were 11% and had clinically amyopathic DM with rapidly progressive interstitial lung disease and higher mortality.